These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31589086)

  • 1. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 2. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Lefebvre P; Pilon D; George DJ
    J Manag Care Spec Pharm; 2024 Jul; 30(7):684-697. PubMed ID: 38950154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation.
    Kaye DR; Khilfeh I; Muser E; Morrison L; Kinkead F; Urosevic A; Lefebvre P; Pilon D; George DJ
    J Med Econ; 2024; 27(1):201-214. PubMed ID: 38204397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study.
    Wang Y; Liu C; Liu C; Lu Y; Ban L; Niu Y
    J Med Econ; 2024; 27(1):361-369. PubMed ID: 38375556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
    Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
    Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use.
    Appukkuttan S; Tangirala K; Babajanyan S; Wen L; Simmons S; Shore N
    Pharmacoecon Open; 2020 Sep; 4(3):439-447. PubMed ID: 31641995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
    Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
    Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [No Abstract]   [Full Text] [Related]  

  • 13. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
    Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
    Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
    Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
    J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
    Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
    Mehra M; Wu Y; Dhawan R
    J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
    Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
    Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.